# A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Source: https://onco.cc/trials/nct06982924/  
OnCo record `nct06982924` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of limertinib and bevacizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.

## Summary

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. is a phase 2, randomised interventional study registered as NCT06982924 by Shanghai Chest Hospital, with a registry enrolment figure of 136 participants, started 2025-06-30 and due to reach its primary completion in 2026-12-30. Interventions recorded: Limertinib+bevacizumab; Limertinib. Conditions listed: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer; PD-L1 Positive. Primary outcome: PFS. Lung eligibility wording from the registry: "Histologically or cytologically confirmed non - squamous non - small cell lung cancer (NSCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: LIBRA
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06982924
- Phase: 2
- Setting: A Prospective, Controlled Phase II Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib Monotherapy as First - Line Treatment for Locally Advanced or Recurrent Metastatic Non - Squamous NSCLC With EGFR Mutations and High PD-L1 Expression.
- Sponsor: Shanghai Chest Hospital
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT06982924: https://clinicaltrials.gov/study/NCT06982924

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Limertinib](https://onco.cc/drugs/limertinib/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06982924.json